Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24

Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr

Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024

Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr

Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024

Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

Mastek partners Innovaccer to transform value-based care and improve patient experience

This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC

Enhertu demonstrated clinically meaningful efficacy in previously treated patients

Lyka’s patent pending Drug Pregabalin Gel 8% w/w receives approval from CDSCO

Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w